Enzolytics Stock

Enzolytics EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Enzolytics (ENZC) as of Aug 20, 2026 is -7,696.47 %.

EBIT/Assets

-7,696.47 %

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Enzolytics is 2026 -7,696.47 % . Operating Income to Assets Ratio (EBIT/Assets) of Enzolytics was 2025 - . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Enzolytics Stock analysis

What does Enzolytics do? Enzolytics Inc is an innovative biotechnology company specializing in the development of effective therapies for combating infectious diseases and cancer. Enzolytics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enzolytics stock

Operating Income to Assets Ratio (EBIT/Assets) of Enzolytics is -7,696.47 % in 2026.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Enzolytics since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Enzolytics with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

Profitability — Enzolytics

All Key Metrics — Enzolytics